NEW YORK (GenomeWeb News) – Scientists at the Whitehead Institute will use $5.3 million over the next three years from Biogen Idec to pursue research projects involving genomics, genetics, immunology, neurology, developmental biology, and other approaches.
Under a new research collaboration agreement, the funding from the Weston, Mass.-based drug developer will support early stage research projects addressing a wide array of disease areas, the Whitehead Institute said yesterday.
These Whitehead investigators will pair up with scientists at Biogen Idec, and together they will develop integrated and collaborative research projects. A joint committee of scientists from Whitehead and Biogen Idec will determine which projects will receive funding.
"This collaboration demonstrates our joint commitment to finding ways to better understand the underlying biology of complex diseases, focusing on innovative initiatives where together we can drive new insights through cutting-edge research," Biogen Idec's CSO Spyros Artavanis-Tsakanos said in a statement.